Homocysteine levels in patients with heart failure with preserved ejection fraction

Cardiology

Volumn 117, Issue 1, 2010, Pages 21-27

  Okuyan, Ertuǧrul ^a   Uslu, Ahmet ^b   Çakar, Mehmet Akif ^c   Sahin, Irfan ^a   Önür, Imran ^a   Enhos, Asim ^a   Biter, Halil Ibrahim ^a   Çetin, Şükrü ^a   Dinçkal, Mustafa Hakan ^a  

^a Bagcilar Research and Training Hospital   (Turkey)

^b Serife Baci State Hospital   (Turkey)

^c Sakarya Training and Research Hospital   (Turkey)

Author keywords

Chronic heart failure; Diastolic dysfunction; Homocysteine

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; HEMOGLOBIN A1C; HOMOCYSTEINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIASTOLIC HEART FAILURE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FILLING; HEART LEFT VENTRICLE WALL MOTION; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SYMPTOM;

AGED; FEMALE; HEART FAILURE, DIASTOLIC; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; LINEAR MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY EDEMA; RISK FACTORS; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 77957149233     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320106     Document Type: Article

References (33)

1. Miyagishima K, Hiramitsu S, Kimura H, Mori K, Ueda T, Kato S, Kato Y, Ishikawa S, Iwase M, Morimoto S, Hishida H, Ozaki Y: Long-term prognosis of chronic heart failure: reduced vs. preserved left ventricular ejection fraction. Circ J 2009; 73: 92-99.
2. Grossman W: Diastolic dysfunction in congestive heart failure. N Engl J Med 1991; 325: 1557-1564.
3. Zile MR, Brutsaert DL: New concepts in dia-stolic dysfunction and diastolic heart failure. 1. Diagnosis, prognosis, and measurements of diastolic dysfunction. Circulation 2002; 105: 1387-1393.
4. Zile MR, Brutsaert DL: New concepts in diastolic dysfunction and diastolic heart failure. 2. Causal mechanism and treatment. Circulation 2002; 105:1503-1508.
5. Aurigemma GP, Gaasch WH: Diastolic heart fa ilure. N Engl J Med 2004; 351: 1097-1105.
6. Zile MR, Baicu CF, Gaasch WH: Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004; 350: 1953-1959.
7. Hogg K, Swedberg K, McMurray J: Heart failure with preserved left ventricular systolic function. J Am Coll Cardiol 2004; 43:317-327.
8. Thom T, Haase N, Rosamond W, Howard V J, Rumsfeld J, Manolio T, Zheng ZJ, Flegal K, O'Donnell C, Kittner S, Lloyd-Jones D, Goff DC Jr, Hong Y, Adams R, Friday G, Furie K, Gorelick P, Kissela B, Marler J, Meigs J, Roger V, Sidney S, Sorlie P, Steinberger J, Was-serthiel-Smoller S, Wilson M, Wolf P: Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006; 113:e85-e151.
9. Refsum H, Smith AD, Ueland PM, Nexo E, Clarke R, McPartlin J, Johnston C, Engbaek F, Schneede J, McPartlin C, Scott JM: Facts and recommendations about total homocys-teine determinations: an expert opinion. Clin Chem 2004; 50:3-32.
10. Stanger O, Herrmann W, Pietrzik K, Fowler B, Geisel J, Dierkes J, Weger M: DACH-LIGA homocystein (German, Austrian and Swiss Homocysteine Society): consensus paper on the rational clinical use of homocysteine, fo-lic acid and B-vitamins in cardiovascular and thrombotic diseases-guidelines and recommendations. Clin Chem Lab Med 2003; 41: 1392-1403. (Pubitemid 37493551)
11. Herrmann W: The importance of hyperho-mocysteinemia as a risk factor for diseases: an overview. Clin Chem Lab Med 2001; 39: 666-674.
12. De Bree A, Verschuren WM, Kromhout D, Kluijtmans LA, Blom HJ: Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease. Pharmacol Rev 2002; 54: 599-618.
13. Austin RC, Lentz SR, Werstuck GH: Role of hyperhomocysteine in endothelial dysfunction and atherothrombotic disease. Cell Death Differ 2004; 11:S56-S64.
14. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, Loscalzo J: Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993; 91:308-318.
15. Woo KS, Chook P, Lolin YI, Cheung AS, Chan LT, Sun YY, Sanderson JE, Metreweli C, Celermajer DS: Hyperhomocysteinemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 1997; 96: 2542-2544.
16. Naruszewicz M, Klinke M, Dziewanowski K, Staniewicz A, Bukowska H: Homocysteine, fibrinogen, and lipoprotein(a) levels are simultaneously reduced in patients with chronic renal failure treated with folic acid, pyridoxine, and cyanocobalamin. Metabolism 2001; 50 : 131-134.
17. Welch GN, Loscalzo J: Homocysteine and atherothrombosis. N Engl J Med 1998; 338: 1042-1050. (Pubitemid 128753793)
18. Joseph J, Joseph L, Shekhawat NS, Devi S, Wang J, Melchert RB, Hauer-Jensen M, Kennedy RH: Hyperhomocysteinemia leads to pathological ventricular hypertrophy in nor-motensive rats. Am J Physiol Heart Circ Physiol 2003; 285:H679-H686.
19. Joseph J, Washington A, Joseph L, Koehler L, Fink LM, Hauer-Jensen M, Kennedy RH: Hyperhomocysteinemia leads to adverse cardiac remodeling in hypertensive rats. Am J Physiol Heart Circ Physiol 2002; 283:H2567-H2574.
20. McKee PA, Castelli WP, McNamara PM, Kannel WB: The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971; 285:1441-1446.
21. Senni M, Redfield MM: Heart failure with preserved systolic function: a different natural history? J Am Coll Cardiol 2001; 38:1277-1282.
22. Galderisi M: Diastolic dysfunction and dia-stolic heart failure: diagnostic, prognostic and therapeutic aspects. Cardiovasc Ultrasound 2005; 3: 9.
23. Devereux RB, Roman MJ, Liu JE, Welty TK, Lee ET, Rodeheffer R, Fabsitz RR, Howard BV: Congestive heart failure despite normal left ventricular systolic function in a population-based sample: the Strong Heart Study. Am J Cardiol 2000; 86:1090-1096.
24. Finkelstein JD: The metabolism of homocys-teine: pathways and regulation. Eur J Pediatr 1998; 157(suppl 2):S40-S44.
25. Finkelstein JD, Martin JJ: Homocysteine. Int J Biochem Cell Biol 2000; 32:385-389.
26. Naruszewicz M, Jankowska EA, Zymlin-ski R, Bukowska H, Millo B, Banasiak W, Ponikowski P: Hyperhomocysteinemia in patients with symptomatic chronic heart failure: prevalence and prognostic importance-pilot study. At herosclerosis 2007; 194: 408-414.
27. Herrmann M, Kindermann I, Muller S, Georg T, Kindermann M, Bohm M, Herr-ma n n W: Relationship of plasma homoc yste-ine with the severity of chronic heart failure. Clin Chem 2005; 51 : 1512-1515.
28. Cesari M, Zanchetta M, Burlina A, Pedon L, Maiolino G, Sticchi D, Pessina AC, Rossi GP: Hyperhomocysteinemia is inversely related with left ventricular ejection fraction and predicts cardiovascular mortality in high-risk coronary artery disease hypertensives. A r terioscler Th romb Vasc Biol 2005; 25:115-121.
29. Bokhari SW, Bokhari ZW, Zell JA, Lee DW, Faxon DP: Plasma homocysteine levels and the left ventricular systolic function in coronary artery disease patients. Coron Artery Dis 2005; 16 : 153-161.
30. Sundstrom J, Sullivan L, Selhub J, Benjamin EJ, D'Agostino RB, Jacques PF, Rosenberg IH, Levy D, Wilson PW, Vasan RS: Relations of plasma homocysteine to left ventricular structure and function: the Framingham Heart Study. Eur Heart J 2004; 25: 523-530.
31. Kennedy RH, Owings R, Shekhawat N, Joseph J: Acute negative inotropic effects of ho-mocysteine are mediated via the endotheli-um. Am J Physiol Heart Circ Physiol 2004; 287:H812-H817.
32. Joseph J, Joseph L, Devi S, Kennedy RH: Effect of anti-oxidant treatment on hyperho-mocysteinemia induced myocardial fibrosis and diastolic dysfunction. J Heart Lung Transplant 2008; 27:1237-1241.
33. Poirier P, Bogaty P, Garneau C, Marois L, Dumesnil JG: Diastolic dysfunction in nor-motensive men with well-controlled type 2 diabetes: importance of maneuvers in echo-cardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care 2001; 24:5-10.